Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies

Abdominal Radiology

Volumn 41, Issue 6, 2016, Pages 1086-1099

  Sirous, Reza ^a   Henegan, John C ^b   Zhang, Xu ^b   Howard, Candace M ^a   Souza, Frederico ^a   Smith, Andrew D ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Anti angiogenic therapy; Imaging biomarker; Metastatic renal cell carcinoma; Tumor response

Indexed keywords

ANGIOGENESIS INHIBITOR; TUMOR MARKER;

ANTIANGIOGENIC THERAPY; CANCER THERAPY; CHOI CRITERIA; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY TEXTURE ANALYSIS; CONTRAST ENHANCEMENT; DEVASCULARIZATION; DYNAMIC CONTRAST ENHANCED ULTRASOUND; ECHOGRAPHY; HEALTH CARE QUALITY; HUMAN; IMAGE ANALYSIS; KIDNEY METASTASIS; META ANALYSIS (TOPIC); MODIFIED CHOI CRITERIA; MORPHOLOGY ATTENUATION SIZE AND STRUCTURE CRITERIA; ONCOLOGICAL PARAMETERS; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; TUMOR DIAMETER SHRINKAGE CRITERIA; TUMOR NECROSIS; TUMOR VOLUME; VASCULAR TUMOR; VASCULAR TUMOR BURDEN CRITERIA; DIAGNOSTIC IMAGING; KIDNEY TUMOR; METASTASIS; PATHOLOGY; RENAL CELL CARCINOMA; X-RAY COMPUTED TOMOGRAPHY;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84975299058     PISSN: 2366004X     EISSN: 23660058     Source Type: Journal    
DOI: 10.1007/s00261-016-0742-7     Document Type: Review

References (63)

1. Brufau BP, Cerqueda CS, Villalba LB, et al. (2013) Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT. Radiographics 33(6):1691–1716
2. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29
3. Heilbrun ME, Remer EM, Casalino DD, et al. (2015) ACR Appropriateness Criteria indeterminate renal mass. J Am Coll Radiol 12(4):333–341
4. Thyavihally YB, Mahantshetty U, Chamarajanagar RS, Raibhattanavar SG, Tongaonkar HB (2005) Management of renal cell carcinoma with solitary metastasis. World J Surg Oncol 3:48
5. Hafez KS, Novick AC, Campbell SC (1997) Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 157(6):2067–2070
6. Muglia VF, Prando A (2015) Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras 48(3):166–174
7. Bianchi M, Sun M, Jeldres C, et al. (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973–980
8. Li P, Wong YN, Armstrong K, et al. (2016) Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer Med 5(2):169–181
9. Coppin C, Porzsolt F, Awa A, et al. (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 1:CD001425
10. Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
11. Cuenod CA, Fournier L, Balvay D, Guinebretiere JM (2006) Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment. Abdom Imaging 31(2):188–193
12. Escudier B, Eisen T, Stadler WM, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134
13. Escudier B, Pluzanska A, Koralewski P, et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111
14. Motzer RJ, Hutson TE, Tomczak P, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124
15. Miller K, Wang M, Gralow J, et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676
16. Hutson TE (2011) Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 16(Suppl 2):14–22
17. Choueiri TK, Escudier B, Powles T, et al. (2015) Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373(19):1814–1823
18. Lombardi G, Zustovich F, Donach M (2012) Dalla Palma M, Nicoletto O, Pastorelli D. An update on targeted therapy in metastatic renal cell carcinoma. Urol Oncol 30(3):240–246
19. Bex A, Fournier L, Lassau N, et al. (2014) Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations. Eur Urol 65(4):766–777
20. Krajewski KM, Guo M, Van den Abbeele AD, et al. (2011) Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 59(5):856–862
21. Nishino M, Ramaiya NH, Choueiri TK (2015) RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. Am J Roentgenol 204(3):W282–W288
22. Kim JH (2016) Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review. Oncotarget 7:13680–13687
23. Nathan PD, Vinayan A, Stott D, Juttla J, Goh V (2010) CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 9(1):15–19
24. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Boven E (2010) Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol 5(2):95–112
25. Smith AD, Lieber ML, Shah SN (2010) Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. Am J Roentgenol 194(1):157–165
26. Sullivan DC, Obuchowski NA, Kessler LG, et al. (2015) Metrology Standards for Quantitative Imaging Biomarkers. Radiology 277(3):813–825
27. Raunig DL, McShane LM, Pennello G, et al. (2015) Quantitative imaging biomarkers: a review of statistical methods for technical performance assessment. Stat Methods Med Res 24(1):27–67
28. Abramson RG, Burton KR, Yu JP, et al. (2015) Methods and challenges in quantitative imaging biomarker development. Acad Radiol 22(1):25–32
29. van der Mijn JC, Mier JW, Broxterman HJ, Verheul HM (2014) Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms. Drug Resist Updat 17(4–6):77–88
30. Figueiras RG, Padhani AR, Goh VJ, et al. (2011) Novel oncologic drugs: what they do and how they affect images. Radiographics 31(7):2059–2091
31. Eichelberg C, Junker K, Ljungberg B, Moch H (2009) Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 55(4):851–863
32. Casalino DD, Remer EM, Bishoff JT, et al. (2014) ACR appropriateness criteria post-treatment follow-up of renal cell carcinoma. J Am Coll Radiol 11(5):443–449
33. Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216
34. Miles KA (1999) Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol 30(3):198–205
35. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM (2010) Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. Am J Roentgenol 194(6):1470–1478
36. Smith AD, Zhang X, Souza F, et al., editors. Vascular tumor burden as a new quantitative CT imaging biomarker for predicting metastatic RCC response to antiangiogenic therapy. ASCO Annual Meeting Proceedings; 2016.
37. Krajewski KM, Franchetti Y, Nishino M, et al. (2014) 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. Oncologist 19(5):507–514
38. Choi H, Charnsangavej C, Faria SC, et al. (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753–1759
39. Smith AD, Souza F, Roda M, Zhang H, Zhang X. MASS Criteria predicts survival in sunitinib treated metastatic RCC—a secondary analysis of a multi-institutional prospective phase III trial. Society of Abdominal Radiology Annual Meeting; 2015.
40. Smith AD, Zhang X, Bryan J, et al. Vascular tumor burden as a new quantitative computed tomography imaging biomarker for predicting metastatic renal cell carcinoma response to anti-angiogenic therapy. Radiology (Under review); 2016.
41. Schmidt N, Hess V, Zumbrunn T, et al. (2013) Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. Eur Radiol 23(3):632–639
42. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E (2010) Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 102(5):803–809
43. Lamuraglia M, Raslan S, Elaidi R, et al. (2016) mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response. Eur Radiol 26(1):278–285
44. Krajewski KM, Nishino M, Franchetti Y, et al. (2014) Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer 120(5):711–721
45. Thian Y, Gutzeit A, Koh DM, et al. (2014) Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib. Radiology 273(2):452–461
46. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM (2013) Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis. Urol Oncol 31(7):1283–1291
47. Miles KA, Ganeshan B, Hayball MP (2013) CT texture analysis using the filtration-histogram method: what do the measurements mean? Cancer Imaging 13(3):400–406
48. Goh V, Ganeshan B, Nathan P, et al. (2011) Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology 261(1):165–171
49. Lamuraglia M, Escudier B, Chami L, et al. (2006) To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 42(15):2472–2479
50. Lassau N, Koscielny S, Albiges L, et al. (2010) Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 16(4):1216–1225
51. Lassau N, Chapotot L, Benatsou B, et al. (2012) Standardization of dynamic contrast-enhanced ultrasound for the evaluation of antiangiogenic therapies: the French multicenter Support for Innovative and Expensive Techniques Study. Invest Radiol 47(12):711–716
52. Fournier LS, Oudard S, Thiam R, et al. (2010) Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 256(2):511–518
53. Hahn OM, Yang C, Medved M, et al. (2008) Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26(28):4572–4578
54. Wang HY, Ding HJ, Chen JH, et al. (2012) Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging 12:464–474
55. Caldarella C, Muoio B, Isgro MA, et al. (2014) The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma. Radiol Oncol 48(3):219–227
56. Farnebo J, Gryback P, Harmenberg U, et al. (2014) Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma. BMC Cancer 14:408
57. Horn KP, Yap JT, Agarwal N, et al. (2015) FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging 15:15
58. Oosting SF, Brouwers AH, van Es SC, et al. (2015) 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med 56(1):63–69
59. Maleddu A, Pantaleo MA, Castellucci P, et al. (2009) 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori 95(3):382–384
60. Turkbey B, Lindenberg ML, Adler S, et al. (2016) PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study. Abdom Radiol 41(1):109–118
61. Middendorp M, Maute L, Sauter B, Vogl TJ, Grunwald F (2010) Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma. Ann Nucl Med 24(6):441–446
62. Namura K, Minamimoto R, Yao M, et al. (2010) Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer 10:667
63. Liu G, Jeraj R, Vanderhoek M, et al. (2011) Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res 17(24):7634–7644